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Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance.
Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis
evasion, cytochrome P450 and P-glycoprotein, were discussed. There was a special focus on leukaemia, breast and ovarian cancer,
and the potential use of positron-emission tomography to study anticancer-drug resistance. The progress made in translating these
findings to the clinic, like Gefitinib, P-glycoprotein phenotyping, or genome-wide analysis technology, was also discussed.
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Approximately 50 scientists and clinicians working in the field
of drug resistance gathered recently for a 1-day workshop at the
Wolfson Conference Centre (Hammersmith Hospital, London) to
discuss their latest results. The meeting was organised by the MRC
Clinical Sciences Centre and was sponsored by Cancer Research
UK. The workshop focused on both basic mechanisms and clinical
applications, with a strong emphasis on translational research.
BASIC MECHANISMS
It has been now widely demonstrated that normal primary cells
become tumorigenic when expressing hTERT, SV40 proteins LT
and ST, and oncogenic ras. We are using the step-wise model of
tumorigenesis (Hahn and Weinberg, 2002) to determine whether
the ability of human primary embryonic skin fibroblasts to
develop drug resistance is exclusive to the transformed state or
extends to premalignant cells. Interestingly, cells at early stages of
the tumorigenesis process were able to develop doxorubicin-
resistant derivatives. This demonstrates that, at least in this cell
model system, the ability to acquire drug resistance is not a
consequence of the accumulation of mutations that occur during
the proliferation of a transformed cell, but it is an intrinsic
characteristic that appears before the complete set of genetic
transforming alterations. We are currently dissecting the minimal
set of genetic alterations necessary to switch on the ability to
acquire drug resistance, and dissecting the drug resistance
signatures by microarray analysis.
Drugs that produce DNA interstrand crosslinks between the
two complementary strands of the double helix, are among the
most widely used and most effective anticancer agents. Victoria
Spanswick (London) described a highly sensitive and robust
method to determine DNA crosslinks in leukaemia, myeloma and
solid tumour samples: the single-cell gel electrophoresis (Comet)
assay. Cells isolated from melphalan-treated multiple myeloma
patients showed between 42 and 100% repair of radiation-induced
DNA crosslinks, whereas no repair was observed in cells from
naive patients. These findings suggest that DNA interstrand
crosslink repair may be an important mechanism of clinical
resistance to melphalan in multiple myeloma (Spanswick et al,
2002). Spanswick and co-workers are currently determining
whether molecules involved in the nucleotide excision repair and
double-strand break repair pathways are implicated in this
process.
The cytochrome P450 enzymes are a large family of constitutive
and inducible haem-containing oxidative enzymes with roles in
the metabolism of xenobiotics and steroid hormone synthesis.
Georgia Pass (Dundee) described the use of a mouse model with a
conditional deletion in the liver cytochrome P450 reductase (HRN)
to study cyclophosphamide (CPA) toxicokinetics and therapeutic
response. CPA is an anticancer prodrug that is dependent on
cytochrome P450 for its therapeutic effectiveness. Pass and co-
workers have demonstrated that in HRN mice the in vitro
metabolism and intrinsic clearance of CPA was over six-fold lower
than in wild-type animals. This, and other in vivo data (Pass et al,
2005), confirms that hepatic metabolism is the major route of CPA
elimination and disposition. It is clear that this powerful model
will undoubtedly produce many more advances in our under-
standing of drug metabolism. Morag McFadyen (Aberdeen)
described some of the P450s that are specifically upregulated in
cancer, their role in drug resistance and different therapeutic
strategies. By far the most interesting is CYP1B1. This is the only
P450 whose expression is not detected at all in normal human
tissues. However, many kinds of cancer, like breast or ovarian,
show activation of CYP1B1 expression. McFadyen described briefly
the main strategies that are being used to tackle P450-associated
drug resistance: (a) the use of prodrugs, (b) clinical inhibitors, and
(c) immunotherapy; for a detailed review see McFadyen et al
(2004). Since CYP1B1 is exclusively expressed in tumour cells, it is
one of the most promising targets for the development of CYP1B1-
specific prodrugs.
Another important mechanism of drug resistance is apoptosis
evasion. Michael Seckl (London) is dissecting the mechanisms by
which fibroblast growth factor 2 (FGF-2) protects small cell lung
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2003). FGF-2 inhibits Smac but not mitochondrial cytochoromc c
release upon exposure to etoposide. Smac/DIABLO promotes
cytochrome c-induced activation of caspases by sequestering the
inhibitor of apoptosis protein (IAP) family of caspase suppressors.
In addition, FGF-2 signalling increases the translation of existing
mRNAs such as BCL2 and BCLXL, XIAP and cellular IAP-1. RNA
interference of IAPs or 40S ribosomal protein S6K2BII prevented
FGF-2- mediated rescue of etoposide killing in SCLC. Thus, FGF-2
protects SCLC cells from chemotherapeutic drugs via post-
transcriptional regulation of several genes, providing multiple
mechanisms for postmitochondrial survival via signalling through
the SK6/MEK/mitogen-activated protein kinase pathway.
Some of the many mechanisms that the cells use to grow in the
presence of a cytotoxic drug are exemplified by the work of Eric
Lam (London) on the role of FoxO (Forkhead bOX-containing
protein, O sub-family) family of transcription factors. Members of
the FoxO family play a role in the downregulation of cellular
responses normally elicited by growth factors activating the PI(3)
kinase signal transduction pathway. In a panel of nine breast
cancer cell lines, expression of FoxO1a and FoxO3a correlated
with the expression of the proapoptotic FoxO target Bim, which
was associated with paclitaxel-induced apoptosis. Gene reporter
experiments in MCF-7 cells suggested that FoxO3a is responsible
for the transcriptional upregulation of Bim. RNA interference
specific for FoxO3a reduced the levels of Bim and inhibited
apoptosis in paclitaxel-treated MCF-7 cells (Sunters et al, 2003). In
leukaemia, FoxO3a regulates cyclin D2 expression. Inhibition of
BCR-ABL by STI571 leads to FoxO3a activation, which in turn
induces the expression of BCL6, culminating in the repression of
cyclin D2 transcription through a STAT5 element in the cyclin D2
promoter (Essafi et al, 2005).
LEUKAEMIA
In acute myeloid leukaemia (AML) there is a clinical correlation
between P-glycoprotein (PGP) expression and chemotherapy
treatment outcome and it is one of the most powerful prognostic
factors. However, the clinical trials with competitive PGP
antagonists have produced mixed and inconclusive results.
According to Monica Pallis (Nottingham), a possible explanation
for such mixed results may be due to the fact that no trials have
been carried out with exclusively PGP-positive patients. Pallis and
co-workers have developed sensitive and robust methods for the
reproducible measurements of PGP in AML blasts permitting
classification of the PGP status of AML patients in the clinical
practice. Pallis’ protocol involves a CD45 gate for blasts and the
modulation of rhodamine 123 efflux by PGP with PSC 833. This
functional analysis has proven more reliable than MRK-16 (a
PGP-specific antibody) binding and has shown no intercentre
variability (Pallis et al, 2005). Therefore, Pallis’ methodology
could now be translated to hospital immunophenotyping labora-
tories. From receiving a marrow sample, the assay takes about 4h
and can be carried out with as few as 3 million cells. Using this
protocol, trial organisers would have the choice of whether to give
PGP modulators to an unsorted cohort or to PGP-positive patients
only.
Contrary to AML, PGP is not associated with drug resistance
in childhood acute lymphoblastic leukaemia (ALL). Andy Hall
(Newcastle) described the use of a single nucleotide polymorphism
(SNP)-based chip to study loss of heterozygosity (LOH). Allelic
imbalance is frequently observed in malignant cells and con-
tributes to the deregulation of cell division and apoptosis through
the deletion of tumour suppressor genes. Although other
techniques such as karyotyping, comparative genomic hybridisa-
tion, or microsatellite analysis, have been used in the past, they are
either of low resolution or laborious to conduct on a genome-wide
scale. The recent introduction of oligonucleotide microarrays
designed for the genome-wide typing of SNPs, with a resolution of
100–200kb, has been used by Hall’s group to characterize
progressive LOH in samples from children with ALL who relapse
after chemotherapy (Irving et al, 2005). Although Hall and co-
workers have used a small number of patients in their preliminary
study, their data suggest that progressive LOH may be a cause of
disease progression and/or drug resistance. The most frequent
abnormality detected was a loss of the INK4 locus at relapse,
suggesting that this abnormality may be commonly associated with
treatment failure. Overall, Hall’s results show that SNP array
analysis is a powerful new tool for the analysis of allelic imbalance
in leukaemic blasts.
BREAST CANCER
Breast cancer accounts for one in four of all female cancers,
making it by far the most common cancer in women in the western
world. Around one in nine women in the USA and UK will develop
breast cancer at some stage in their lives. Breast cancer treatment
involves surgical removal of the tumour, but this is ineffective if
malignant cells have escaped from the site of the primary tumour.
Discovery of the involvement of the ovarian hormone oestrogen
paved the way for the development of therapies that inhibit
oestrogen synthesis or block its receptor. In many cases, however,
these therapies fail due to recurrent endocrine-resistant tumours
and much effort is being made to elucidate the mechanisms that
underlie resistance to endocrine therapies. Iain Hutcheson’s
(Cardiff) group has developed an in vitro model system to dissect
the altered signalling pathways in tamoxifen-resistant (TAMR)
cells. Altered growth factor signalling, notably epidermal growth
factor receptor (EGFR), c-erbB2, and insulin-like growth factor I
receptor (IGF-IR) make a significant contribution to the develop-
ment of antioestrogen resistance. As a consequence, several Phase
II studies have been initiated examining Gefitinib (Iressa, a EGFR-
selective tyrosine kinase inhibitor) monotherapy in TAMR breast
cancer. Hutcheson has shown that TAMR cells that have become
in vitro resistant to Gefitinib, are highly invasive, and that IGF-IR
signalling is involved in these changes. Current efforts in
Hutcheson’s lab are aimed at using these cell model systems to
test combination therapies to prevent the development of
antioestrogen and antigrowth factor resistance (Nicholson et al,
2003).
Following the significant enhanced response of breast cancer
patients to docetaxel neoadjuvant chemotherapy (Smith et al,
2002), Andrew Schofield’s (Aberdeen) group is dissecting the
mechanism that could mediate resistance to this drug in cell model
systems by combining comparative genomic hybridisation (CGH)
and expression profiling with cDNA microarrays. Several candi-
date genes: PTEN, MDR1, Bax p27Kip1, among many others, were
highlighted (McDonald et al, 2005). The use of RNAi to
downregulate p27Kip1, has indicated that docetaxel resistance in
these cells is very likely the result of altered expression of multiple
genes.
Genome-wide expression profiling is a powerful tool that is
becoming increasingly important not only for the classification of
tumours, but also for the prediction of clinical outcome. John
Foekens (Rotterdam) described the use of gene expression
profiling analysis in breast cancer. The promoter DNA methylation
status of 117 genes was studied in a cohort of 200 steroid hormone
receptor-positive tumours of patients who received the antioestro-
gen tamoxifen as first-line treatment for recurrent breast cancer.
The methylation status of 10 genes was significantly associated
with clinical outcome of tamoxifen therapy. Of these, PSATI was a
predictor of tamoxifen therapy response (Martens et al, 2005). In
another study, Foekens and co-workers have identified a specific
signature for lymph-node-negative patients at high risk of distant
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avoid adjuvant systemic therapy or to choose less aggressive
therapeutic options for lymph-node-negative patients who lack
this signature (Wang et al, 2005).
OVARIAN CANCER
Approximately, one out of 48 women in the western world develop
epithelial ovarian cancer. In patients with organ-confined cancers,
surgery alone is curative in more than 90% of cases. However, in
most patients the tumour has disseminated beyond the ovaries
by the time it is diagnosed; in these cases, combined treatment
with surgery and chemotherapy is necessary, but acquired drug
resistance is common (Agarwal and Kaye, 2003). Roshan Agarwal’s
(Sutton) research focuses on determining altered expression
patterns in ovarian cancer drug resistance. Instead of using cell
model systems, Agarwal is using patient biopsies analysed by a
combined approach of CGH and expression prolifing with
commercial BACs and expression microarrays. By using tumour
cells from ascitic fluids purified by BerEP4, an epithelial marker
antibody, Agarwal has obtained a 95% pure population of tumour
cells suitable for expression profiling. Although the work is still in
progress, preliminary results indicate that some of the candidate
genes, like tubulin, had a previous association with paclitaxel drug
resistance, thus validating Agarwal’s methodology.
PRECLINICAL APPLICATIONS
Catharine West (Manchester) discussed the potential of positron-
emission tomography (PET) to study anticancer-drug resistance.
At present, most of drug resistance-PET is limited to animal or
preclinical studies. The most widely used PET imaging probe is the
glucose analogue
18F-FDG whose uptake is used in the diagnosis
to distinguish between benign and malignant lesions, and for the
staging of cancer. 5-Fluorouracil (5-FU) is widely used as an
anticancer treatment; however, drug resistance remains a sig-
nificant problem that limits its efficacy. Pathways leading to 5-FU
resistance include decreased uptake due to extracellular catabolism
or poor tumour perfusion, increased efflux once inside the cell,
increased intracellular degradation and metabolic inactivation.
How and to what extent these different pathways contribute to
drug resistance in patients and their variability is not known.
5-Fluorouracil labelled with
18F has been used in PET studies to
increase the understanding of these mechanisms, which could be
exploited in the further development of this drug or its analogues,
or to aid the development of biomodulation approaches for
increasing their efficacy (West et al, 2004).
CONCLUDING REMARKS
The use of cell model systems, in spite of all their shortcomings,
continue to be one of the main tools researchers have to identify
candidate molecules and dissect the signalling pathways involved
in drug resistance. In many cases, these basic studies lead to
clinical trials such as Gefitinib for tamoxifen-resistant breast
cancer.
Reproducible methodology has been developed to determine the
PGP status of AML patients permitting the routine phenotyping of
these patients.
Genome-wide analysis methodologies (CGH, SNP-arrays, and
expression microarrays) are being used at increasing pace. In
many cases, some of which were reported in this workshop, we
have progressed from a purely descriptive status to the prediction
of the outcome of therapy or of the development of recurrent
disease by specific gene signatures. It is difficult to foresee how
quickly these technologies will translate to the clinical practice but
one of the major drawbacks, discussed informally at coffee time, is
obviously their current cost.
Drug resistance is a complex and dynamic phenotype. Unravel-
ling the basic mechanisms giving rise to this multifactorial
phenomenon and translating these finding in the design of novel
therapeutic strategies in the clinic is the next challenge that both
scientists and clinicians working in this field have for the years to
come.
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